Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1959 1
1962 1
1981 1
1982 2
1983 2
1985 1
1986 3
1987 1
1988 2
1991 2
1992 3
1993 1
1994 1
1995 1
1996 1
1997 2
1999 1
2000 5
2001 2
2002 5
2003 2
2004 5
2005 7
2006 7
2007 17
2008 10
2009 21
2010 27
2011 26
2012 25
2013 19
2014 19
2015 22
2016 20
2017 24
2018 21
2019 16
2020 20
2021 23
2022 30
2023 28
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382
Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.
Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group. Schuetz P, et al. JAMA. 2009 Sep 9;302(10):1059-66. doi: 10.1001/jama.2009.1297. JAMA. 2009. PMID: 19738090 Clinical Trial.
Management of the Mangled Extremity.
Farrelly E, Tarapore R, Lindsey S, Wieland MD. Farrelly E, et al. Among authors: wieland md. Surg Clin North Am. 2024 Apr;104(2):385-404. doi: 10.1016/j.suc.2023.10.006. Epub 2023 Nov 17. Surg Clin North Am. 2024. PMID: 38453309 Review.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Community Engagement With Vulnerable Populations.
Wieland ML, Doubeni CA, Sia IG. Wieland ML, et al. Mayo Clin Proc. 2020 Sep;95(9S):S60-S62. doi: 10.1016/j.mayocp.2020.05.041. Epub 2020 Jun 22. Mayo Clin Proc. 2020. PMID: 32807521 Free PMC article. No abstract available.
397 results